Clinical Trial

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 23, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with relapsed or refractory osteosarcoma and other sarcomas.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-04-13; most recent amendment 2024-08-22.
Status change: Not Yet Recruiting → Recruiting 2023-07-19
Trial Details
NCT Number NCT05830123
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Osteosarcoma, Sarcoma
Enrollment 170 participants
Start Date 2023-06-08
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-23